News for Axsome Therapeutics, Inc. (0HKF.L)

Axsome Therapeutics (AXSM) will release its Q2 2025 financial results on August 4, 2025. A conference call to discuss the results is scheduled for 8:00

Summary Axsome Therapeutics Inc (AXSM), a pioneering biopharmaceutical company focused on central nervous system (CNS) disorders, announced on July 9, 2025, tha

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. ( AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected […]

On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.

Morgan Stanley analyst Sean Laaman has announced a new price target for Axsome Therapeutics (AXSM), setting it at USD 190.00. This target is now officially reco

Axsome Therapeutics (AXSM) is actively partnering with the Alzheimer's disease advocacy community to highlight the increasing prevalence of Alzheimer's in the U

Summary On June 20, 2025, Axsome Therapeutics Inc (AXSM), a prominent biopharmaceutical company specializing in central nervous system disorders, announced its

**media[660164]**

Axsome Therapeutics (AXSM) to present three key clinical studies on SYMBRAVO® at AHS annual meeting. Presentations to cover efficacy on migraine disabi

**media[658229]**

Axsome Therapeutics (AXSM) is marking Migraine and Headache Awareness Month by partnering with the Association of Migraine Disorders. This year, under the theme

Axsome Therapeutics (AXSM) supports Migraine and Headache Awareness Month in June 2025 alongside the Association of Migraine Disorders. Over 12 "Miles for M

**media[651583]**

Axsome Therapeutics, under the ticker AXSM, has introduced SYMBRAVO, a new prescription medication available in the United States for the acute treatment of mig

Axsome Therapeutics (AXSM) receives continual support from HC Wainwright & Co., as the investment firm reiterates its Buy rating on the stock. The most recent a

Axsome Therapeutics launches SYMBRAVO for acute migraine treatment in the U.S. SYMBRAVO offers rapid pain relief within 2 hours, lasting

SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side o